Mourant advises BeiGene, Ltd. on Hong Kong’s biggest biotech IPO
16 August 2018
Leading offshore law firm, Mourant Ozannes, has advised Chinese Nasdaq-listed biotech company BeiGene, Ltd. on its $903 million dual primary listing in Hong Kong.
The listing marks Hong Kong’s biggest biotech IPO to date, and is the first dual primary listing of a Nasdaq-listed biotech company.
BeiGene, Ltd. is a biopharmaceutical company focused on developing and commercialising molecularly targeted and immuno-oncology drugs for the treatment of cancer.
The Mourant team advised on the Cayman Islands legal aspects of the deal and was led by Partner Robert Duggan, with Senior Associate Hannah Crews.
Skadden, Arps, Slate, Meagher & Flom, Goodwin Proctor and Fangda Partners acted as onshore counsel to BeiGene, Ltd. Davis Polk & Wardwell and JunHe advised the joint sponsors and underwriters.
About Mourant
Mourant is a law firm-led, professional services business with over 60 years' experience in the financial services sector. We advise on the laws of the British Virgin Islands, the Cayman Islands, Guernsey, Jersey and Luxembourg and provide specialist entity management, governance, regulatory and consulting services.
